Analysts have raised their price target for Lisata Therapeutics slightly, increasing it from $13.00 to $13.00 per share. This reflects updated projections for profitability and valuation metrics.
What's in the News
- Lisata Therapeutics and Catalent announced a global product license agreement that allows Catalent to use Lisata's certepetide in antibody-drug conjugates developed with SMARTag technology. Lisata could receive over $10 million in milestone payments and revenue sharing on future sales and partnerships (Key Developments).
- Certepetide, Lisata's proprietary iRGD cyclic peptide, is being evaluated in combination therapies to enhance tumor targeting, penetration, and treatment outcomes for solid tumors. It has demonstrated favorable safety and clinical activity in ongoing and completed trials (Key Developments).
- Lisata reported encouraging preliminary data from the Phase 1/2a CENDIFOX trial for pancreatic ductal adenocarcinoma. Results are scheduled to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research in September 2025 (Key Developments).
- Certepetide has received Fast Track and Orphan Drug Designation for pancreatic cancer in the U.S. and E.U., as well as Orphan Drug and Rare Pediatric Disease Designations for glioma and osteosarcoma in the U.S. (Key Developments).
- The company has gathered significant preclinical data indicating that certepetide can enhance delivery of a wide range of anti-cancer therapies, including immunotherapies and RNA-based therapeutics (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $13.00 per share, indicating no revision in the projected fair value.
- The discount rate has risen slightly, moving from 6.97 percent to approximately 6.99 percent.
- Revenue growth projections are stable, holding at roughly 83.83 percent year-over-year.
- The net profit margin forecast has increased from 14.37 percent to 16.03 percent, reflecting improved expectations for profitability.
- The future P/E (Price-to-Earnings ratio) has fallen significantly from 166.60x to 104.62x, suggesting lower valuation multiples on projected earnings.
Have other thoughts on Lisata Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.